CYCLOHEXANEDIOL DERIVATIVES

Abstract: The compound, (E)-(1R,3R)-5-[(R)-11-hydroxy-7,11-dimethyl-dodec-2-enylidene]-cyclohe xane-1,3-diol of formula (I) is useful in the treatment or prevention of hyperproliferative skin diseases, particularly psoriasis, basal cell carcinomas, disorders of keratinization and keratosis; or for reversing the conditions associated with photodamage.

Description: Cvclohexanediol derivatives The invention relates to the novel compound, (E)-(lR,3R)-5-[(R)-ll- hydroxy-7,ll-dimethyl-dodec-2-enylidene]-cyclohexane-l,3-diol of the formula I: The compound of the invention (hereinafter the Compound) can be utilized to treat or prevent hyperproliferative skin diseases such as psoriasis, basal cell carcinomas, disorders of keratinization and keratosis; neoplastic diseases; disorders of the sebaceous glands such as acne and seborrhoic dermatitis. The Compound can also be utilized in reversing the conditions associated with photodamage, particularly for the oral or topical treatment of the skin damaged through sun exposure, the effects of wrinkling, elastosis and premature aging. The present invention furthermore relates to a process for the preparation of the Compound, pharmaceutical compositions containing the Compound, and the use of the Compound for the treatment and prevention of the above mentioned disorders, and for the manufacture of pharmaceutical compositions for the treatment and prevention of the above mentioned disorders. The Compound can be obtained by cleavage of the silyl protecting groups contained in a compound of formula II: wherein L is preferably tert-butyldimethyl-silyl (TBDMS) and L' preferably trimethyl-silyl [Si(Me) 3 ] . The cleavage can be effected by tetrabutylammom ' um fluoride (TBAF) in a solvent such as THF. The intermediates II, which are novel and as such are a further object of the present invention, can be prepared in a manner known per se, e.g. as shown in the following reaction scheme, where L is TBDMS and L' is Si(Me) 3 , and as described in detail in the Example hereinbelow. Wittig- Horner 1] MCPBA 2] Pd/C H 2 LiAlH 4 cat. TPAP t NMO Silylation Ph Ph TBDMSO f* x r OTBDMS nBuLi/ THF -78 π (L = TBDMS, L' = SiMβ 3 I nBu 4 NF/ THF Example (E)-(lR,3R)-5-[(R)-ll-Hydroxy-7,ll-dimethyl-dodec-2-enylidene]- cyclohexane-l,3-diol was prepared as follows: A) 8.55 g of carefully dried (3R,5R)-[2-[3,5-bis-(t-butyldimethyl- silanyloxy)-cyclohexylidene] -ethyl] -diphenyl-phosphine oxide (Tetrahedron Lett. 32, 7663 (1991)) was dissolved in 90 ml of abs. THF and treated at -78° with 10.9 ml of nBuLi (1.6M, hexane). After 20 minutes, 2.27 g of (S)-5,9-dimethyl-9-trimethylsilanyloxy-decanal, dissolved in a small amount of THF, was added dropwise to the deep red solution. The mixture was kept for 0.5 h at -78° and for 4 h at ambient temperature. After quenching with crashed ice/ KH 2 PO 4 , the product was extracted twice with ether, washed with water and brine, dried over sodium sulfate and the solvents removed i.N. Flash chromatography (SiO 2 , hexane/ AcOEt) yielded in the less polar fractions 3.840 g of (R)-l- [(3R,5R)-3,5-bis-(tert-butyldimethyl-silanyloxy)-cyclohexylidene]-7,ll- dimethyl-ll-trimethylsilanyloxy-dodec-2-ene, as colorless oil, which was deprotected as described in the following paragraph. 2.40 g of phosphine oxide, which had been used in excess, were recovered in the more polar fractions. B) 4.88 g of the silylated diene, prepared as described above, were treated with 5.25 equivalents of anhydr. TBAF (0.5M inTHF) at 50° for 2 h. The reaction mixture was poured onto crashed ice, extracted twice with AcOEt, washed with water and brine, dried over sodium sulfate and evaporated to dryness. Flash chromatography (SiO 2 , hexane/ AcOEt=l/2) yielded 2.304 g of the title compound as colorless oil, contaminated with roughly 10% of the Z-isomer. MS: (M-H 2 O) + 306, (M-2H 2 O) + 288; ΝMR: (1H, DMSO, δ, TMS) 0.83 (d, 3H), 1.05 (s, 6H), 1.05-1.43 (m, 17H), 1.62 (t, 2H), 1.9-2.15 (m, 4H), 2.23 (dd, 1H), 2.36 (dd, 1H), 3.83 (m, 2H), 4.04 (s, 1H, OH), 4.42 (d, 1H, OH), 4.45 (d, 1H, OH), 5.54 (dt, 1H), 5.75 (d, 1H), 6.24 (dd, 1H); IR (cm "1 ): 3369, 2929, 1461, 1377, 1216, 1049, 963. The starting decanal derivative was prepared as follows: a) 16.05 g of triethyl phosphonoacetate was dissolved in 160 ml of abs. THF and treated at 0° with 8.32 g of KOtBu. After 1 h at that temperature, 8.16 g of (-)-citronellal, dissolved in 30 ml of abs. THF, was added to the white suspension. 1.5 h later, the reaction was quenched by pouring onto crashed ice/ NH 4 C1, extracted twice with ether, washed with water and brine, dried over sodium sulfate and evaporated to dryness. Flash chromatography (SiO 2 , hexane/ AcOEt=97/3)produced 8.84 g of (E)-(S)-5,9-dimethyl-deca-2,8-dienoic acid ethyl ester as colorless oil. b) 13.54 g of 3-chloro-perbenzoic acid (MCPBA, 70%) was dissolved in 30 ml of CH 2 C1 2 and cooled to 0°. 8.84 g of (E)-(S)-5,9-dimethyl-deca-2,8- dienoic acid ethyl ester dissolved in 15 ml of CH 2 C1 2 , was slowly added and the mixture kept for an additional 0.5 h in the ice bath. The reaction was then quenched by pouring onto crashed ice/ sodium pyrosulfite, extracted twice with AcOEt, washed with 2N NaOH, water and brine, dried over sodium sulfate and evaporated to dryness to yield 9.59 g of (5R)-7-((RS)-3,3-dimethyl-oxiranyl)-5-methyl-hept-2-enoic acid ethyl ester as 1/1 epimeric mixture, sufficiently pure for the next step. c) 9.59 g of (5S)-7-((RS)-3,3-dimethyl-oxiranyl)-5-methyl-hept-2-enoic acid ethyl ester was hydrogenated at RT in 57 ml of AcOEt over 960 mg of Pd C (5%) for 6 h. At that time, GC analysis indicated the complete disappearance of starting material. Filtration and flash chromatography (SiO 2 , hexane/ AcOEt=9/l) afforded 7.98 g of (5R)-7-((RS)-3,3-dimethyl- oxiranyl)-5-methyl-heptanoic acid ethyl ester (roughly 1/1 epimeric mixture) as colorless oil. d) 7.98 g of (5R)-7-((RS)-3,3-dimethyl-oxiranyl)-5-methyl-heptanoic acid ethyl ester was dissolved in 130 ml of abs. THF and treated carefully at -25° with 2.49 g of LiAlH 4 . The reaction mixture was kept for 0.5 h at -20° and for 5 h at ambient temperature. The excess of reagent was destroyed by successively adding AcOEt and MeOH. 3N aq. NaOH was then added in order to hydrolyse the aluminum alkoxides, but in such small quantities that the formation of a second aq. layer was avoided. Filtration over sodium sulfate, washing with ether, and evaporation to dryness yielded a crude product which was purified by flash chromatography (SiO 2 , hexane/ AcOEt=l/l) to deliver 4.59 g of (R)- 5,9-dimethyl-decane-l,9-diol as colorless oil, 96% pure according to GC. e) 5.68 g of 4-methylmorpholine N-oxide (monohydrate) and 31.5 g of molecular sieves (powder, 4A) in 200 ml of abs. CH 2 C1 2 were stirred for 0.25 h at ambient temperature. 500 mg of tetrapropylammonium perrhutenate was added, before a solution of 4.59 g of (R)-5,9-dimethyl- decane-l,9-diol in 20 ml of abs. CH 2 C1 2 was added within 1 h. 15 minutes later, the reaction mixture was filtered and the solvents removed i.N. Flash chromatography (SiO 2 , hexane/ AcOEt=7/3) afforded 3.103 g of (S)-9-hydroxy-5,9-dimethyl-decanal as colorless oil, 98.7% pure according to GC. f) 3.10 g of (S)-9-hydroxy-5,9-dimethyl-decanal was dissolved in 60 ml of abs. CH 2 C1 2 and treated successively at 0° with 57 mg of DMAP, 7.0 ml of ΝEt 3 and 3.1 ml of TMS-C1. The reaction mixture was kept for 30 minutes at RT and then poured onto crashed ice, extracted twice with ether, washed twice with water and brine, dried over sodium sulfate and evaporated to dryness. Flash chromatography (SiO 2 , hexane/ AcOEt=95/5) yielded 3.90 g of (S)-5,9-dimethyl-9-trimethylsilanyloxy- decanal as colorless oil, 98.6% pure according to GC. Pharmaceutical properties of the Compound can be determined according to the following procedure: The Compound was orally applied to Gδttingen minipigs at different doses for seven days. The pigs were daily observed as to adverse effects (behavior, mobility, stool). At day seven bromodeoxyuridine (4 mg/kg) was injected intravenously in the treated pigs and one hour later skin biopsies (6 mm diameter) and blood were taken from the animals for analysis. The skin biopsies were fixed in formalin, and paraffin sections were prepared using standard procedures. Using standard immuno-histochemical techniques, cells in the S-phase (DNA synthesis phase) were labelled by binding of a specific monoclonal antibody against the thymidine analogue, bromodeoxyuridine. The number of labelled epidermal cells per unit of length along the surface was taken as a measure of epidermal proliferative activity. Results The Compound was extremely well tolerated and caused an increase in epidermal proliferation in a large dose range (100-4000 μg/kg) without any adverse effect (neither visible nor with regard to clinical chemical parameters). Conclusion Enhancement of epidermal proliferation is indicative of epidermal repair mechanisms, e.g. in photodamage. Furthermore, an increase of epidermal proliferation in vivo in normal epidermis is indicative of a normalization of the epidermal proliferation in hyperproliferative disorders, as is known for instance for retinoids. The Compound can be administered orally, for the treatment or prevention of hyperproliferative skin diseases such as psoriasis, basal cell carcinomas, disorders of keratinization, and keratosis, or for the treatment of neoplastic diseases, to warmblooded animals which need such treatment. More specifically, the Compound as described above can be administered orally to an adult human in dosages that are in the range of about 50 μg to 3 mg per day for the treatment of the above diseases. The Compound can be administered topically, for the treatment or prevention of hyperproliferative skin diseases such as psoriasis, to warmblooded animals which need such treatment. More specifically, the Compound can be administered topically in dosages that are in the range of about 50 μg to 5 mg per gram of topical formulation per day, for the treatment of the above diseases. The Compound can also be administered orally or topically for reversing the conditions associated with photodamage. The dosage of the Compound can vary within wide limits depending on the illness to be treated, the age and the individual condition of the patient and on the mode of administration and will, of course, be fitted to the individual requirements in each particular case. Oral dosage forms comprising the Compound, may be incorporated in capsules, tablets and the like with pharmaceutically acceptable carrier materials. Illustrative of such carrier materials which may be incorporated into capsules, and the like are the following: an emulsifier such as polyethylene glycol; a solubilizer such as a short chain triglyceride, e.g. Miglyol; a binder such as gum tragacanth, acacia, corn starch, or gelatin; an excipient such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch or algenic acid; a lubricant such as magnesium stearate, a sweetening agent such as sucrose, lactose, or saccharin; a flavoring agent such as peppermint, oil of wintergreen or cherry. Various other materials may be present as coating or to otherwise modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar, or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propyl parabens as preservatives, a dye, and a flavoring such as cherry or orange flavor. Topical dosage forms comprising the Compound include: ointments and creams encompassing formulations having oleaginous, absorbable, water-soluble and emulsion-type bases such as petrolatum, lanolin, polyethylene glycols and the like. Lotions are liquid preparations and vary from simple solutions to aqueous or hydroalcoholic preparations containing finely divided substances. Lotions can contain suspending or dispersing agents, for example, cellulose derivatives such as ethyl cellulose, methyl cellulose, and the like; gelatin or gums, which incorporate the active ingredient in a vehicle made up of water, alcohol, glycerin and the like. Gels are semi-solid preparations made by gelling a solution or suspension of the active ingredient in a carrier vehicle. The vehicles, which can be hydrous or anhydrous, are gelled using a gelling agent, such as, carboxy polymethylene, and neutralized to a proper gel consistency with the use of alkalies, such as, sodium hydroxide and amines, such as, polyethylenecocoamine. As used herein, the term "topical" denotes the use of the active ingredient, incorporated in a suitable pharmaceutical carrier, and applied at the site of the disorder for the exertion of local action. Accordingly, the topical composition include those pharmaceutical forms in which the Compound is applied externally by direct contact with the skin. The topical dosage forms comprise gels, creams, lotions, ointments, powders, aerosols and other conventional forms for applying medication to the skin obtained by admixing the Compound with known pharmaceutical topical carrier materials. The following pharmaceutical compositions can be prepared in a manner known per se: Example A Soft Gelatine Capsule mg/Capsule Compound 50 Butylated Hydroxytoluene (BHT) 0.016 Butylated Hydroxyanisole (BHA) 0.016 Fractionated Coconut Oil (Neobee M-5) or Miglyol 812 q.s. 160.0 Example B Soft Gelatine Capsule mε/Carjsule Compound 50 α-Tocopherol 0.016 Miglyol 812 q.s. 160.0 Examp - C Topical Cream mg/g Compound 20 Cetyl Alcohol 1.5 Stearyl Alcohol 2.5 Span 60 (Sorbitan monostearate) 2.0 Arlacel 165 (Glyceryl monostearate 4.0 and polyoxyethylene glycol stearate blend) Tween 60 (polysorbate 60) 1.0 Mineral Oil 4.0 Propylene Glycol 5.0 Propylparaben 0.05 BHA0.05 Sorbitol Solution 2.0 Edetate Disodium 0.01 Methylparaben 0.18 Distilled Water q.s. Examnle D Topical ointment g/g Compound 20 Propylenglycol exc. ad ung. pro 1 g

Claims: Claims 1. The compound, (E)-(lR,3R)-5-[(R)-ll-hydroxy-7,ll-dimethyl- dodec-2-enylidene]-cyclohexane-l,3-diol of the formula I: 2. The compounds of formula II: wherein L and L' silyl protecting groups. 3. Pharmaceutical composition, particularly for the treatment or prevention of hyperproliferative skin diseases, specially psoriasis, basal cell carcinomas, disorders of keratinization and keratosis; or for reversing the conditions associated with photodamage, comprising the compound of claim 1 as active ingredient and pharmaceutically acceptable carriers. 4. Process for preparing the compound of formula I as in claim 1 which comprises cleaving the silyl-protection groups L and L' contained in a compound of formula 5. The compound of claim 1 for use in the treatment or prevention of hyperproliferative skin diseases, particularly psoriasis, basal cell carcinomas, disorders of keratinization and keratosis; or for reversing the conditions associated with photodamage. 6. The use of the compound of claim 1 for the manufacture of pharmaceutical compositions for the treatment or prevention of hyperproliferative skin diseases, particularly psoriasis, basal cell carcinomas, disorders of keratinization and keratosis; or for reversing the conditions associated with photodamage. 7. Novel compounds, intermediates, formulations and uses substantially as described therein.

Inventors: BAUER FRANZ, COURTNEY LAWRENCE F, BAUER, FRANZ, COURTNEY, LAWRENCE, F.
Applicants: HOFFMANN LA ROCHE, F.HOFFMANN-LA ROCHE AG
Application year: 1998
Main classification: C07C35
IPC codes: A61K31, A61P17, A61P35, C07C35, C07F7